IgG-mediated anaphylaxis to a Synthetic long peptide vaccine containing a B cell epitope can be avoided by slow-release formulation

Esther D. Quakkelaar, Marieke F. Fransen, Wendy W. C. van Maren, Joost Vaneman, Nikki M. Loof, Sandra H. van Heiningen, J. Sjef Verbeek, Ferry Ossendorp, Cornelis J. M. Melief

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Synthetic long peptides (SLP) are a promising vaccine modality to induce therapeutic T cell responses in patients with chronic infections and tumors. We studied different vaccine formulations in mice using SLP derived from carcinoembryonic Ag. We discovered that one of the SLP contains a linear Ab epitope in combination with a CD4 epitope. Repeated vaccination with this carcinoembryonic Ag SLP in mice shows improved T cell responses and simultaneously induced high titers of peptide-specific Abs. These Abs resulted in unexpected anaphylaxis after a third or subsequent vaccinations with the SLP when formulated in saline. Administration of low SLP doses in the slow-release vehicle IFA prevented the anaphylaxis after repeated vaccination. This study underscores both the immunogenicity of SLP vaccination, for inducing T cell as well as B cell responses, and the necessity of safe administration routes. Copyright © 2014 by The American Association of Immunologists, Inc. 0022-1767/14/$16.
Original languageEnglish
Pages (from-to)5813-5820
JournalJournal of Immunology
Volume192
Issue number12
DOIs
Publication statusPublished - 2014

Cite this

Quakkelaar, E. D., Fransen, M. F., van Maren, W. W. C., Vaneman, J., Loof, N. M., van Heiningen, S. H., ... Melief, C. J. M. (2014). IgG-mediated anaphylaxis to a Synthetic long peptide vaccine containing a B cell epitope can be avoided by slow-release formulation. Journal of Immunology, 192(12), 5813-5820. https://doi.org/10.4049/jimmunol.1302337